Sienna Biopharmaceuticals, Inc. (SNNAQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
1,000 - Avg. Volume
0 - Market Cap (intraday)
30 - Beta (5Y Monthly) 67.56
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
www.siennabio.comRelated News
Performance Overview: SNNAQ
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNNAQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNNAQ
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.23
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.10%
Return on Equity (ttm)
-140.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-47.95M
Diluted EPS (ttm)
-1.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
11.33M
Total Debt/Equity (mrq)
44.49%
Levered Free Cash Flow (ttm)
-36.09M
Research Analysis: SNNAQ
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell